In preclinical models, pharmacological inhibitors of IDO1 have therapeutic utility in various diseases, including cancer, HIV and influenza (Yang et al., 2020b; Chang et al., 2020; Chi et al., 2020). The gene discussed is IDO1; the disease is cancer.